Cargando…
Medication use by early-stage breast cancer survivors: a 1-year longitudinal study
PURPOSE: The aim of this study is to characterize the patterns of medication use by early-stage breast cancer (ESBC) survivors from diagnosis to 1 year post-chemotherapy. METHODS: A single-center longitudinal study was conducted with ESBC patients diagnosed between December 2011 and June 2014. Data...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766201/ https://www.ncbi.nlm.nih.gov/pubmed/26404861 http://dx.doi.org/10.1007/s00520-015-2950-z |
_version_ | 1782417620089176064 |
---|---|
author | Loh, Kep Yong Ng, Terence Lee, Chee Ping Ng, Raymond Chan, Alexandre |
author_facet | Loh, Kep Yong Ng, Terence Lee, Chee Ping Ng, Raymond Chan, Alexandre |
author_sort | Loh, Kep Yong |
collection | PubMed |
description | PURPOSE: The aim of this study is to characterize the patterns of medication use by early-stage breast cancer (ESBC) survivors from diagnosis to 1 year post-chemotherapy. METHODS: A single-center longitudinal study was conducted with ESBC patients diagnosed between December 2011 and June 2014. Data on the medication use of individual patients were retrieved from prescription databases, supplemented by records from the National Electronic Health Records. The data covered the period from ESBC diagnosis to 1 year post-chemotherapy. Medication types were classified according to the World Health Organization’s Anatomical Therapeutic Chemical classification system, and medication for chronic diseases was created by adapting a list of 20 chronic diseases provided by the U.S. Department of Human and Health Services. RESULTS: Of the 107 patients involved in the study (mean age 51.1 ± 8.4 years; 78.5 % Chinese), 46.7 % manifested non-cancer comorbidities, of which hypertension (24.3 %) was the most prevalent, followed by hyperlipidemia (13.1 %) and diabetes (5.6 %). Calcium channel blockers (12.1 %) and lipid-modifying agents (11.2 %) were the most common chronic medication types used before chemotherapy, and their use persisted during chemotherapy (10.3 and 11.2 %, respectively) and after chemotherapy (11.2 and 13.1 %, respectively). Hormonal therapy was the predominant post-chemotherapy medication (77.6 %). A statistically significant increase (p < 0.0001) was observed in the mean number of chronic disease medication classes prescribed to patients between the pre-chemotherapy (0.53 ± 1.04) and chemotherapy (0.62 ± 1.08) periods and between the chemotherapy and post-chemotherapy (1.63 ± 1.35) periods. CONCLUSIONS: There is an increase in trend of chronic medication usage in breast cancer survivors after cancer treatment. This study provides important insights into the design of medication management programs tailored to this population. Future studies should incorporate a control population to improve the interpretation of study results. |
format | Online Article Text |
id | pubmed-4766201 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-47662012016-04-04 Medication use by early-stage breast cancer survivors: a 1-year longitudinal study Loh, Kep Yong Ng, Terence Lee, Chee Ping Ng, Raymond Chan, Alexandre Support Care Cancer Original Article PURPOSE: The aim of this study is to characterize the patterns of medication use by early-stage breast cancer (ESBC) survivors from diagnosis to 1 year post-chemotherapy. METHODS: A single-center longitudinal study was conducted with ESBC patients diagnosed between December 2011 and June 2014. Data on the medication use of individual patients were retrieved from prescription databases, supplemented by records from the National Electronic Health Records. The data covered the period from ESBC diagnosis to 1 year post-chemotherapy. Medication types were classified according to the World Health Organization’s Anatomical Therapeutic Chemical classification system, and medication for chronic diseases was created by adapting a list of 20 chronic diseases provided by the U.S. Department of Human and Health Services. RESULTS: Of the 107 patients involved in the study (mean age 51.1 ± 8.4 years; 78.5 % Chinese), 46.7 % manifested non-cancer comorbidities, of which hypertension (24.3 %) was the most prevalent, followed by hyperlipidemia (13.1 %) and diabetes (5.6 %). Calcium channel blockers (12.1 %) and lipid-modifying agents (11.2 %) were the most common chronic medication types used before chemotherapy, and their use persisted during chemotherapy (10.3 and 11.2 %, respectively) and after chemotherapy (11.2 and 13.1 %, respectively). Hormonal therapy was the predominant post-chemotherapy medication (77.6 %). A statistically significant increase (p < 0.0001) was observed in the mean number of chronic disease medication classes prescribed to patients between the pre-chemotherapy (0.53 ± 1.04) and chemotherapy (0.62 ± 1.08) periods and between the chemotherapy and post-chemotherapy (1.63 ± 1.35) periods. CONCLUSIONS: There is an increase in trend of chronic medication usage in breast cancer survivors after cancer treatment. This study provides important insights into the design of medication management programs tailored to this population. Future studies should incorporate a control population to improve the interpretation of study results. Springer Berlin Heidelberg 2015-09-25 2016 /pmc/articles/PMC4766201/ /pubmed/26404861 http://dx.doi.org/10.1007/s00520-015-2950-z Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Loh, Kep Yong Ng, Terence Lee, Chee Ping Ng, Raymond Chan, Alexandre Medication use by early-stage breast cancer survivors: a 1-year longitudinal study |
title | Medication use by early-stage breast cancer survivors: a 1-year longitudinal study |
title_full | Medication use by early-stage breast cancer survivors: a 1-year longitudinal study |
title_fullStr | Medication use by early-stage breast cancer survivors: a 1-year longitudinal study |
title_full_unstemmed | Medication use by early-stage breast cancer survivors: a 1-year longitudinal study |
title_short | Medication use by early-stage breast cancer survivors: a 1-year longitudinal study |
title_sort | medication use by early-stage breast cancer survivors: a 1-year longitudinal study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766201/ https://www.ncbi.nlm.nih.gov/pubmed/26404861 http://dx.doi.org/10.1007/s00520-015-2950-z |
work_keys_str_mv | AT lohkepyong medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy AT ngterence medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy AT leecheeping medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy AT ngraymond medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy AT chanalexandre medicationusebyearlystagebreastcancersurvivorsa1yearlongitudinalstudy |